



Practitioner's Docket No. MPI99-017DV1AM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hodge, Martin R., et al

Application No.: 09/894,749

Group No.: 1652

Filed: June 27, 2001

Examiner: Rao, M. N.

For: NOVEL RGS-CONTAINING MOLECULES AND USES THEREOF

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

AMENDMENT TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Amendment Transmittal which includes a request for extension of time (3 pages – in duplicate);
 - b. Amendment and Response (5 pages);
 - c. Statement of Biological Culture Deposit (3 pages);
 - d. ATTC Deposit Receipt (1 page); and
 - e. Postcard Receipt.

STATUS

2. Applicant is other than a small entity.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a two month extension:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.



Signature

Date: June 14, 2004

Diana Gentile
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI99-017DV1AM

Fee: \$420.00

Extension fee due with this request \$420.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY	
Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate	Addit. Fee
Total	0	Minus	0	=	0	\$18.00	\$0.00
Indep.	0	Minus	0	=	0	\$86.00	\$0.00
First Presentation of Multiple Dependent Claims			0			\$290.00	\$0.00
						Total Addit. Fee	\$0.00

Total additional fee for claims required \$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$420.00 (which includes the \$420.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

Practitioner's Docket No. MPI99-017DV1AM

7. Correspondence Address

Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

June 14, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820



Practitioner's Docket No. MPI99-017DV1AM

1652/\$
8/16
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Hodge, Martin R., et al		
Application No.:	09/894749	Group No.:	1652
Filed:	June 27, 2001	Examiner:	RAO, M. N.
For:	NOVEL RGS-CONTAINING MOLECULES AND USES THEREOF		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir: In response to the Office action of January 14, 2004, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.

06/18/2004 MAHMED1 00000026 501668 09894749

01 FC:1252 420.00 DA

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Diana Gentile
Signature

Diana Gentile

(type or print name of person certifying)

Date: 14 June 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

IN THE SPECIFICATION

At page 1, first paragraph, please replace the text with the following paragraph:

This application is a divisional of U.S. Application Serial No. 09/244,314, filed February 4, 1999, now U.S. Patent No. 6,274,362, herein incorporated by reference in its entirety.

At page 5, line 18 through line 28, please replace the paragraphs with the following text:

Figure 1 provides the amino sequences for the h16395 and m1975 proteins. Figure 1A and B provide the human (SEQ ID NO:2) and murine (SEQ ID NO:4) sequences, respectively; the RGS domain is underlined. Figure 1C provides the alignment of the human sequence with the murine orthologue.

Figure 2 shows the amino acid sequence alignment for the proteins encoded by h16395 (SEQ ID NO:2) with human RGS2, RGS4, and RGS5. The RGS proteins share closest homology to human RGS5 protein (about 44% sequence identity for the human sequence) as compared to 38% and 39% for RGS2 and RGS4, respectively. The sequence identity was determined by the Clustal method. The region of homology is observed for the RGS domains, amino acids 82-201, with little homology observed for the N-terminal, 1-81, and C-terminal, 202-235, amino acids.